A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
- Study Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study With an Open-Label Treatment Period of Fremanezumab Administered Subcutaneously Monthly or Quarterly for the Preventive Treatment of Migraine in Adult Chinese Patients
- Teva Identifier
- TV48125-CNS-30088
- ClinicalTrials.gov Identifier
- NCT05458011
- Study Status
- Completed
- Trial Condition(s)
- Migraine Headache
- Interventions
- Drug: Fremanezumab | Drug: Placebo
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 70 Years
- Trial Duration
- September 30, 2022 - June 13, 2024
- Phase
- Phase 3